Nurix Shares Slump 35% After Hours After Sanofi Ends Drug Development
Sanofi notified Nurix Therapeutics that it is discontinuing development of experimental oral drug SAR448272, which it licensed from Nurix.
Shares of Nurix Therapeutics, Inc. (NRIX) slumped 35% after hours on Tuesday after the company said that its partner Sanofi (SNY) has discontinued development of the experimental oral drug called SAR448272 that it licensed from Nurix.Paris-headquartered Sanofi notified Nurix that it is ending the e…